Century Therapeutics (IPSC) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio (QTTB) has outperformed Century Therapeutics (IPSC) over the past year, gaining 217.1% versus a gain of 129.0%. Over five years, QTTB leads with a -92.8% price change compared with -93.4% for IPSC. Q32 Bio is the larger company by market cap ($228.9 million vs $226.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | QTTB |
|---|---|---|
| Share price | $1.25 | $7.69 |
| Market cap | $226.34M | $228.93M |
| 1-day change | -2.34% | -3.75% |
| YTD return | +28.64% | +140.66% |
| 1-year return | +128.98% | +217.06% |
| 5-year return | -93.37% | -92.84% |
| P/E ratio (TTM) | — | 2.44 |
| EPS (TTM) | $-0.93 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $23.57 |
| 52-week low | $0.435 | $1.91 |
| Distance from 52-week high | -58.88% | -67.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +280.00% | +414.95% |
| Average volume | 649.61K | 1.37M |
| Shares outstanding | 181.08M | 29.77M |
| Employees | 78 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed IPSC by 88.1 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
IPSC vs QTTB FAQ
Which is bigger, Century Therapeutics or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $228.93M compared with $226.34M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or QTTB?
QTTB returned +217.06% over the past 12 months, compared with +128.98% for IPSC (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Q32 Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics and Biotechnology: Pharmaceutical Preparations for Q32 Bio.